SCHEMBL711631

SCHEMBL711631

Cc1c(OCC2COCOC2)ccnc1C[S+]([O-])c1nc2ccccc2[nH]1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 5/20 0.40
RAB9A P51151 5/20 0.40
CYP2C9 P11712 4/20 0.40
CYP1A2 P05177 2/20 0.40
CYP3A4 P08684 2/20 0.40
CYP2D6 P10635 2/20 0.40
CYP2C19 P33261 2/20 0.40
WDR5 P61964 3/20 0.39
KMT2A Q03164 3/20 0.39
ENGASE Q8NFI3 3/20 0.39
DDAH1 O94760 2/20 0.39
ALDH1A1 P00352 2/20 0.39
LMNA P02545 2/20 0.39
ADORA3 P0DMS8 2/20 0.39
MAPT P10636 2/20 0.39
HPGD P15428 2/20 0.39
TBXA2R P21731 2/20 0.39
NPY1R P25929 2/20 0.39
ADORA1 P30542 2/20 0.39
OPRM1 P35372 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL714067 0.99 CYP2C9 (0.40) NPC1RAB9ACYP2C9CYP1A2CYP3A4
SCHEMBL714068 0.99 CYP2C9 (0.40) NPC1RAB9ACYP2C9CYP1A2CYP3A4
SCHEMBL712132 0.92 CYP2C9 (0.40) NPC1RAB9ACYP2C9CYP1A2CYP3A4
SCHEMBL711793 0.91 CYP2C9 (0.39) NPC1RAB9ACYP2C9CYP1A2CYP3A4
SCHEMBL711792 0.91 CYP2C9 (0.39) NPC1RAB9ACYP2C9CYP1A2CYP3A4
SCHEMBL710422 0.90 CYP2C9 (0.40) NPC1RAB9ACYP2C9CYP1A2CYP3A4
SCHEMBL711988 0.89 CYP2C9 (0.39) NPC1RAB9ACYP2C9CYP1A2CYP3A4
SCHEMBL10207745 0.89 CYP2C9 (0.38) NPC1RAB9ACYP2C9CYP1A2CYP3A4
SCHEMBL712782 0.89 CYP2C9 (0.39) NPC1RAB9ACYP2C9CYP1A2CYP3A4
SCHEMBL712783 0.89 CYP2C9 (0.39) NPC1RAB9ACYP2C9CYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124780-B2 Benzimidazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-02-28 US claimed
US-20090203911-A1 BENZIMIDAZOLE COMPOUND MIYAZAWA SHUHEI 2009-08-13 US claimed
US-8124780-B2 Benzimidazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2012-02-28 US disclosed
EP-1870409-B1 BENZIMIDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-05-12 EP disclosed
EP-1870409-B1 BENZIMIDAZOLE COMPOUNDS EISAI R&D MAN CO LTD (JP) 2010-05-12 EP disclosed
US-20090203911-A1 BENZIMIDAZOLE COMPOUND MIYAZAWA SHUHEI 2009-08-13 US disclosed
US-7425634-B2 Benzimidazole compound EISAI R&D MANAGEMENT CO., LTD. (JP) 2008-09-16 US disclosed
EP-1870409-A1 BENZIMIDAZOLE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-12-26 EP disclosed
EP-1870409-A1 BENZIMIDAZOLE COMPOUND Eisai R&D Management Co., Ltd. (JP) 2007-12-26 EP disclosed
US-20070015782-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-18 US disclosed
US-20070015782-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-18 US disclosed
US-20070010542-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-11 US disclosed
US-20070010542-A1 Benzimidazole compound EISAI CO., LTD. 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070010542-A1 Benzimidazole compound HRH2, GIPR, HRH4 NPC1 1355/4885RAB9A 1686/4885CYP2C9 1229/4885
US-20090203911-A1 BENZIMIDAZOLE COMPOUND HRH2, HRH4, HRH1 NPC1 1544/4885RAB9A 1821/4885CYP2C9 1734/4885
US-20070015782-A1 Benzimidazole compound HRH2, GIPR, HRH4 NPC1 1355/4885RAB9A 1686/4885CYP2C9 1229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.